4-(2,6-二氯苯基)-3-氧代丁酸乙酯 | 221121-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2,6-二氯苯基)-3-氧代丁酸乙酯
• 英文名称: ethyl 4-(2,6-dichlorophenyl)-3-oxobutanoate
• 英文别名: ethyl 4-(2,6-dichlorophenyl)acetylacetate；ethyl 3-oxo-4-phenylbutanoate
• CAS: 221121-45-5
• 化学式: C₁₂H₁₂Cl₂O₃
• 分子量: 275.131
• InChiKey: AVYVYBSVLSCWTE-UHFFFAOYSA-N

物化性质

• 沸点：
  348.2±32.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2,6-二氯苯基)-3-氧代丁酸乙酯 在 sodium ethanolate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 4-[(2,6-dichlorophenyl)methyl]-2-isobutylsulfanyl-1H-pyrimidin-6-one
  参考文献：
  名称：

  5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones:  Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives

  摘要：

  Molecular modeling analysis of compounds belonging to the recently published series of dihydroalkoxy-benzyl-oxopyrimidines (DABOs), such as S-DABOs and DATNOs, gave support to the design of new 2,6-disubstituted benzyl-DABO derivatives as highly potent and specific inhibitors of the HIV-1 reverse transcriptase (RT). To follow up on the novel DABO derivatives, we decided to investigate the effect of electron-withdrawing substituents in the benzyl unit of the S-DABO skeleton versus their anti-HIV-1 activity. Such chemical modifications impacted the inhibitory activity, especially when two halogen units were introduced at positions 2 and 6 in the phenyl portion of the benzyl group bound to C-6 of the pyrimidine ring. Various 5-alkyl-2-(alkyl(or cycloalkyl)thio)-6-(2,B-dichloro(or 2, 6-difluoro)phenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones were then synthesized and tested as anti-HIV-1 agents in both cell-based and enzyme (recombinant reverse transcriptase, rRT) assays. Among the various mono- and disubstituted phenyl derivatives, the most potent were those containing a 6-(2,6-difluorophenylmethyl) substituent (F-DABOs), which showed EC50's ranging between 40 and 90 nM and selectivity indexes up to greater than or equal to 5000. An excellent correlation was found between EC50 and IC50 values which confirmed that these compounds act as inhibitors of the HIV-1 RT. The structure-activity relationships of the newly synthesized pyrimidinones are presented herein.

  DOI：

  10.1021/jm980260f
• 作为产物：
  描述：

  以 乙醇 为溶剂， 以75%的产率得到4-(2,6-二氯苯基)-3-氧代丁酸乙酯
  参考文献：
  名称：

  对5-羟基苯并[g]吲哚-3-羧酸乙酯及其生物立体异构体作为抑制炎症的5-LO / m-PGES-1双重抑制剂的结构进行优化的结构见解

  摘要：

  花生四烯酸（AA）级联产生的促炎介质，例如前列腺素（PGs）和白三烯（LTs）的释放在引发，维持和调节炎症过程中起着至关重要的作用。新出现的5-脂氧合酶（5-LO）和微粒体前列腺素E 2合酶-1（mPGES-1）的双重抑制剂，同时阻止PGE 2和LT的形成，是一种非常有趣的药物。更好的炎症相关疾病药物治疗的候选药物。根据先前的研究，我们在此进行了基于结构的苯并[g]吲哚-3-羧酸酯衍生物的详细设计，揭示了影响这两种酶活性的几个新关键因素。2-（3,4-二氯苄基）-5-羟基-1H-苯并[g]吲哚-3-羧酸乙酯（4 b， RAF-01）和2-（3,4-二氯苯基）-5-羟基-1H-苯并[g]吲哚-3-羧酸乙酯（7 h， RAF-02）成为最活跃的化合物系列。另外，与选定的基于结构的类似物一起，两种衍生物均显示出显着的体内抗炎特性。 总之，建模和实验研究导致发现了新的候选化合物，这些化合物易于作为炎症途径的多靶点抑制剂进行进一步开发。

  DOI：

  10.1016/j.ejmech.2018.05.041

文献信息

• BICYCLIC INHIBITORS OF ALK
  申请人：Vasudevan Anil

  公开号：US20140171429A1

  公开（公告）日：2014-06-19

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R 1 , R 2 , R 3 , X, Y, Z, A, B, G 1 , m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及式(1)的化合物或药用可接受的盐，式(1)中R1、R2、R3、X、Y、Z、A、B、G1、m和n的定义在说明中。本发明还涉及含有所述化合物的组合物，用于抑制激酶如ALK以及治疗癌症等疾病的方法。
• [EN] BICYCLIC INHIBITORS OF ANAPHASTIC LYMPHOMA KINASE<br/>[FR] INHIBITEURS BICYCLIQUES DE LA KINASE DES LYMPHOMES ANAPLASIQUES
  申请人：ABBOTT LAB

  公开号：WO2012097479A1

  公开（公告）日：2012-07-26

  Disclosed are compounds of formula (Ⅰ) and their pharmaceutical acceptable salts, wherein R1, R2, R3, X, Y, Z, A, B, G1, m and n are defined in the description. The compositions containing the said compounds used for inhibiting kinases such as anaphastic lymphoma kinase (ALK) and methods of treating diseases such as cancer are disclosed.

  公开了公式（Ⅰ）的化合物及其药用盐，其中R1、R2、R3、X、Y、Z、A、B、G1、m和n在描述中有定义。公开了含有上述化合物的组合物，用于抑制激酶如间变性淋巴瘤激酶（ALK）以及治疗癌症等疾病的方法。
• [EN] BICYCLIC INHIBITORS OF ALK<br/>[FR] INHIBITEURS BICYCLIQUES DE L'ALK
  申请人：ABBOTT LAB

  公开号：WO2012097683A1

  公开（公告）日：2012-07-26

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R1, R2, R3, X, Y, Z, A, B, G1, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及化合物的公式（1）或药用可接受盐，公式（1）中R1、R2、R3、X、Y、Z、A、B、G1、m和n的定义在说明中。本发明还涉及含有上述化合物的组合物，用于抑制激酶如ALK并治疗癌症等疾病的方法。
• Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988
  作者：Corinne E. Augelli-Szafran、David C. Horwell、Clare Kneen、Daniel F. Ortwine、Martyn C. Pritchard、Terri S. Purchase、Bruce D. Roth、Bharat K. Trivedi、David Hill、Nirmala Suman-Chauhan、Louise Webdale

  DOI：10.1016/0968-0896(96)00185-x

  日期：1996.10

  A study of structure-activity relationships of a series of 'dipeptoid' CCK-B receptor antagonists was performed in which variations of the phenyl ring were examined while the [(2-adamantyloxy)carbonyl]-alpha-methyl-R)-tryptophan moiety of the potent antagonist CI-988 was kept constant. Since the main focus of this study was phenyl substituent variation, series design techniques were employed to insure

  进行了一系列“二肽” CCK-B受体拮抗剂的结构-活性关系的研究，其中检查了[[2-金刚烷氧基）羰基]-α-甲基-R]-色氨酸部分的苯环变异强效拮抗剂CI-988的药代保持恒定。由于这项研究的主要重点是苯基取代基的变化，因此采用了系列设计技术来确保理化性质（亲脂性，空间性，电子性）以及位置取代的充分传播。对26个和16个类似物进行的QSAR分析显示，CCK-B亲和力与苯环取代基的整体大小和亲脂性相关（即较小的基团与效价增加相关，最佳pi接近）。分别为零）。进一步的研究表明，对苯基取代基的尺寸和电子性质可能与CCK-B亲和力有关。短而大的（支链）吸电子基团可以看到亲和力增加。具有小的对位取代基的类似物似乎具有约1000倍的CCK-B选择性，这表明CCK-B结合的选择性对苯环取代敏感。源自这项研究的4-F-苯基二肽样物质对CCK-B受体具有极高的亲和力（IC50 = 0.08 nM），并且具有
• Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1<i>H</i>-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3<i>H</i>)-one As Potential HIV-1 Inhibitors
  作者：Zengjun Fang、Dongwei Kang、Lingzi Zhang、Boshi Huang、Huiqing Liu、Christophe Pannecouque、Erik De Clercq、Peng Zhan、Xinyong Liu

  DOI：10.1111/cbdd.12524

  日期：2015.10

  synthesized using the simple and efficient CuAAC reaction, and biologically evaluated as inhibitors of HIV‐1. Among them, the most active HIV‐1 inhibitor was compound 4‐((4‐((4‐(2,6‐dichlorobenzyl)‐5‐methyl‐6‐oxo‐1,6‐dihydropyrimidin‐2‐ylthio)methyl)‐1H‐1,2,3‐triazol‐1‐yl)methyl)benzenesulfonamide (B5b7), which exhibited similar HIV‐1 inhibitory potency (EC50 = 3.22 μm) compared with 3TC (EC50 = 2.24 μm)

  使用简单有效的CuAAC反应合成了一系列在C-2侧链上具有取代的1,2,3-三唑部分的新型S-DABO衍生物，并对其进行了生物学评估，将其作为HIV-1的抑制剂。其中最活跃的HIV-1抑制剂是化合物4-（（4-（（4-（2,6-二氯苄基）-5-甲基-6-氧代-1,6-二氢嘧啶-2-基硫基）甲基） -1H-1,2,3-三唑-1-基）甲基）苯磺酰胺（B5b7） ，其表现出类似的HIV-1抑制效力（EC 50  = 3.22  μ米）与3TC（EC相比50  = 2.24  μ米）。这些化合物均未显示出对HIV-2复制的抑制作用。简要讨论了这些新衍生物的初步构效关系（SAR）。